How Biogen’s Aduhelm Bet Became A Commercial Bust
Pink Sheet
In mid-April, CMS released their final National Coverage Determination for Aduhelm, indicated for Alzheimer’s disease, which required patients to be enrolled in a randomized clinical trial. That guidance is in line with what ICER recommended after our report and public meeting on Aduhelm -- the independent appraisal committee unanimously determined that the evidence was not adequate to demonstrate that Aduhelm provided a net health benefit. Pink Sheet’s Mandy Jackson and Mary Jo Laffler explained:
"Aduhelm hit the market at a list price of $56,000 per year, catching many in the field by surprise given the large number of patients potentially eligible for treatment and the big impact the drug could have on payers’ budgets, particularly Medicare. The price far exceeded the Institute for Clinical and Economic Review (ICER)'s estimate that aducanumab would be appropriately priced at $2,500-$8,300 annually."
Pink Sheet
In mid-April, CMS released their final National Coverage Determination for Aduhelm, indicated for Alzheimer’s disease, which required patients to be enrolled in a randomized clinical trial. That guidance is in line with what ICER recommended after our report and public meeting on Aduhelm -- the independent appraisal committee unanimously determined that the evidence was not adequate to demonstrate that Aduhelm provided a net health benefit. Pink Sheet’s Mandy Jackson and Mary Jo Laffler explained:
"Aduhelm hit the market at a list price of $56,000 per year, catching many in the field by surprise given the large number of patients potentially eligible for treatment and the big impact the drug could have on payers’ budgets, particularly Medicare. The price far exceeded the Institute for Clinical and Economic Review (ICER)'s estimate that aducanumab would be appropriately priced at $2,500-$8,300 annually."